Topical PDE-4 Inhibitors are Emerging for Psoriasis Treatment

J Cutan Med Surg. 2021 Jan-Feb;25(1):109-110. doi: 10.1177/1203475420960429. Epub 2020 Sep 30.

Authors

Zainab Ridha¹, Lydia Ouchene², Elena Netchiporouk³, Melinda J Gooderham^{4

5}

Affiliations

¹ 12369 Faculty of Medicine, Université Laval, Quebec, QC, Canada.
² 12367 Faculty of Medicine, McGill University, Montreal, QC, Canada.
³ 54473 Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.
⁴ SKiN Centre for Dermatology, Peterborough, ON, Canada.
⁵ Division of Dermatology, Queen's University, Kingston, ON, Canada.

PMID: 32998515
DOI: 10.1177/1203475420960429

No abstract available

Keywords: PDE-4 inhibitors; psoriasis; roflumilast; topical treatment.

Publication types

Letter

MeSH terms

Administration, Topical
Adult
Female
Humans
Male
Phosphodiesterase 4 Inhibitors / administration & dosage*
Psoriasis / drug therapy*
Randomized Controlled Trials as Topic
Severity of Illness Index

Substances

Phosphodiesterase 4 Inhibitors